Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Parasites & Vectors|July 22, 2011
Modelling age-heterogeneous Schistosoma haematobium and S. mansoni survey data via alignment factorsNadine Schur, Jürg Utzinger, Penelope VounatsouPlos Neglected Tropical Diseases|October 3, 2012
Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasisNadine Schur, Penelope Vounatsou, Jürg UtzingerStatistics in Medicine|April 13, 2011
Modelling the geographical distribution of co-infection risk from single-disease surveysNadine Schur, L Gosoniu, G Raso, et al.Journal of Medical Economics|October 16, 2024
Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in SwitzerlandNadine Schur, Andrea Favre-Bulle, Michael Flori, et al.International Journal of Educational Development|December 27, 2016
The relationship between parental education and children's schooling in a time of economic turmoil: The case of East Zimbabwe, 2001 to 2011Erica Pufall, Jeffrey W Eaton, Constance Nyamukapa, et al.Journal of the International AIDS Society|November 24, 2015
The effects of household wealth on HIV prevalence in Manicaland, Zimbabwe - a prospective household census and population-based open cohort studyNadine Schur, Adrian Mylne, Phyllis Mushati, et al.Journal of Clinical Epidemiology|September 19, 2019
A scoping review shows that several nonvalidated budget planning tools for randomized trials are availableBenjamin Speich, Viktoria Gloy, Nadine Schur, et al.AIDS (London, England)|September 16, 2015
Do HIV prevalence trends in antenatal clinic surveillance represent trends in the general population in the antiretroviral therapy era? The case of Manicaland, East ZimbabweSimon Gregson, Kanika Dharmayat, Monique Pereboom, et al.Plos One|November 10, 2016
Rising Levels of HIV Infection in Older Adults in Eastern ZimbabweJoel Negin, Simon Gregson, Jeffrey W Eaton, et al.Pharmacoeconomics|April 1, 2021
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in SwitzerlandNadine Schur, Kapil Gudala, Umakanth Vudumula, et al.Pageof 4